About this course

Across major cardiovascular outcome trials, sodium-glucose co-transporter 2 (SGLT2) inhibitors have consistently reduced the risk of heart failure (HF) in patients with diabetes and established cardiovascular disease. This e-learning module provides an overview of the latest real-world evidence of SGLT2 inhibitors for the prevention of HF and cardiorenal outcomes.

Learning outcomes

• Understand the burden of HF and the associated guidelines for its prevention
• Apply real-world evidence of SGLT2 inhibitors for the prevention of HF and cardiorenal outcomes
• Utilize the latest robust clinical evidence on the use of SGLT2 inhibitors for treating patients with HF, irrespective of diabetes status.

Topics covered

• Global prevalence of HF and classification
• Guidance on use of biomarkers to screen for patients at risk of HF
• Key finding and implications for clinical practice of the EMPA-REG OUTCOME, DAPA-HF and EMPEROR-Reduced studies
• Role of SGLT2 inhibitors as renal protectants based on the CREDENCE study